Search
ezetimibe add-on to statin for effectiveness (EASE) trial
Study characteristics:
- community based, manufacturer sponsored, randomized trial
- 3 of 6 authors employed by sponsor
3030 patients on statins at start of study
- largely atorvastatin, pravastatin, simvastatin 10-40 mg QD
- at least 6 weeks of statin therapy prior to start of study
- patients had not reached NCEP LDL cholesterol target levels
- mean LDL cholesterol = 129 mg/dL on statin monotherapy
Treatment:
- ezetimibe 10 mg QD vs placebo, while continuing statin dose
Results: (after 6 weeks)
- LDL cholesterol decreased 26% in the ezetimibe group vs 3% in the placebo group
- NCEP LDL cholesterol target levels reached by 71% of ezetimibe group vs 21% of target group
- no serious adverse effects reported
Related
ezetimibe (Zetia)
HMG CoA reductase inhibitor (statin)
General
clinical trial
References
- Journal Watch 25(13):104, 2005
Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE,
Palmisano J.
A community-based, randomized trial of ezetimibe added to
statin therapy to attain NCEP ATP III goals for LDL cholesterol
in hypercholesterolemic patients: the ezetimibe add-on to
statin for effectiveness (EASE) trial.
Mayo Clin Proc. 2005 May;80(5):587-95.
PMID: 15887425
- Hurley DL, Isley WL.
Getting there: statin plus ezetimibe for low-density
lipoprotein cholesterol goals.
Mayo Clin Proc. 2005 May;80(5):585-6. No abstract available.
PMID: 15887424